TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28935146
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (65 g, 2148 mg polyphenols)
Study: 28935146
Drug: Mate tea
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mate tea (3 g, 107 mg total phenols, 84.24 mg chlorogenic acid)
Study: 18806764
Drug: LDL apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL apheresis (LA) combined with conventional therapy (CT)
Study: 18806764
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) only
Study: 15161800
Drug: Early insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insulin response (EIR)
Study: 15161800
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity index (S(i))
Study: 7659484
Drug: Whole‐cell vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐cell vaccines
Study: 7659484
Drug: One vaccine
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vaccine without detectable FIM
Study: 2695280
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg bd (n = 6)
Study: 26938814
Drug: Chlorthalidone/amiloride (12.5/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone/amiloride (12.5/2.5 mg)
Study: 28225315
Drug: Collaborative interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collaborative interventions including standardized insulin infusion protocols, hypoglycemia prevention bundles, audit and feedback, education, and measure‐vention
Study: 26439577
Drug: Chamomilla L.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122) (Group A; n = 45)
Study: 24386561
Drug: Pitavastatin 2mg
Normalized name: PITAVASTATIN 2MG TAB
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin 2mg once daily for 4 weeks
Study: 9304176
Drug: Captopril (CTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (CTP group, n = 15), 12.5 mg every 8 hours orally, from 24 hours before surgery
Study: 1253193
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg practolol administered orally
Study: 1253193
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg practolol, iv
Study: 22921454
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 12 sessions
Study: 15462115
Drug: Purified omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified omega-3 fatty acids (PFA) at a very low dose (0.85 g EPA and 0.57 g PHA)
Study: 9241099
Drug: Perindopril (2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2‐4 mg daily)
Study: 3760480
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy with Adriamycin, Vincaleucoblastin, Bleomycin, Fluorouracil and Ifosfamid monthly for 10 months
Study: 3760480
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intraperitoneal chemotherapy with the same drugs
Study: 26482056
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (ChEIs) continuation
Study: 15892403
Drug: suxamethonium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium (1 mg kg(‐1))
Study: 12590430
Drug: Hospital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital therapy without methadone
Study: 10593465
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (EPI) with bolus doses of morphine via an epidural catheter
Study: 10593465
Drug: Intraarticular analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular analgesia (IA) with 1 mg of morphine applied at the end of the operation and subsequent PCA
Study: 10593465
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (Control) with PCA only
Study: 7159688
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg oral dose) from Brand A
Study: 7159688
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg oral dose) from Brand B
Study: 24611906
Drug: Fucoidan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucoidan (500 mg once daily before breakfast for 3 months)
Study: 11409222
Drug: Proportional assist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proportional assist ventilation (PAV) with 9.8 (± 2.1) cm H2O/L and 3.3 (± 1.0) cm H2O/L/sec of volume assist and flow assist
Study: 1233250
Drug: Strophanthin K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strophanthin K (0.125 and 0.25 MG)
Study: 1233250
Drug: Lanatoside C
Normalized name: lanatoside C
DrugBank: Lanatoside C (DB13467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanatoside C (0.4, 0.8 and 1.6 mg)
Study: 25406300
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mononuclear cell (BMC) therapy
Study: 18290996
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg abacavir
Study: 18290996
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg nevirapine
Study: 16404741
Drug: DVd (pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVd (pegylated liposomal doxorubicin 40 mg/m², vincristine 1.4 mg/m², dexamethasone 40 mg Days 1-4)
Study: 16404741
Drug: VAd (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAd (conventional doxorubicin 9 mg/m² per day, vincristine 0.4 mg per day, dexamethasone reduced dose)
Study: 14744180
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (neuroleptics)
Study: 14744180
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Placebo and Active treatment)
Study: 11412157
Drug: Ropivacaine combined
Normalized name: bupivacaine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine combined with sufentanil 0.75 microg.ml‐1
Study: 9646213
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for four weeks plus amoxicillin 3 g daily during the first and second week (Group A)
Study: 9646213
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for 4 weeks plus placebo for two weeks (Group B)
Study: 2885366
Drug: Clotiazepam 5
Normalized name: clotiazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotiazepam 5 mg
Study: 2885366
Drug: Clotiazepam 10
Normalized name: clotiazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotiazepam 10 mg
Study: 2885366
Drug: Clotiazepam 20
Normalized name: clotiazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotiazepam 20 mg
Study: 30052729
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of chemotherapy
Study: 16687979
Drug: Tretin-X (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretin-X (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Study: 16687979
Drug: Retin-A (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retin-A (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Study: 8867397
Drug: Early nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early nutritional support (enteral or parenteral feeding) with appropriate caloric and protein requirement as soon as hemodynamic status was stabilized.
Study: 8867397
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method with administration of hypo caloric intravenous regimen and supplement with oral diet as soon as bowel function returned.
Study: 1363640
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil alone (500 mg)
Study: 1363640
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil with food (500 mg)
Study: 6377829
Drug: Glipizide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (5 mg orally)
Study: 6377829
Drug: Glipizide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (oral administration)
Study: 20571433
Drug: venlafaxine‐XR 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine‐XR 225 mg/d
Study: 20571433
Drug: mirtazapine 45
Normalized name: mirtazapine 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirtazapine 45 mg/d
Study: 16286163
Drug: Fasudil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (up to 80 mg three times daily)
Study: 2323078
Drug: Lozenge containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge containing 11 mg L-menthol
Study: 499107
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of 20% glucose per kg body weight (Group II)
Study: 499107
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g chloropropamide (Group III)
Study: 26781338
Drug: FospropofolFD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FospropofolFD 20 mg/kg
Study: 25079934
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g dose of cephalexin 30‐60 min before excision
Study: 21507197
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg dipyrone (D15 group)
Study: 21507197
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg dipyrone (D40 group)
Study: 19730804
Drug: Asacol (400‐4800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol (400‐4800 mg single dose)
Study: 19730804
Drug: Asacol (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol (3600 mg/day for 7 days)
Study: 19730804
Drug: Asacol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol (single and multiple doses)
Study: 17312063
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of swirled mesentery and mushroom shape
Study: 9934937
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for up to 12 weeks
Study: 2138972
Drug: Corrosion inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrosion inhibitor component of cutting fluids
Study: 730419
Drug: Org GC
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org GC 94 (45 mg/day for 14 days)
Study: 20951543
Drug: Trauma Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma Management Therapy (TMT)
Study: 26501533
Drug: naproxen +
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen + oxycodone/acetaminophen
Study: 15606550
Drug: High-dose cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytotoxic treatment and autologous bone marrow transplantation
Study: 10568870
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sucrose and nonnutritive sucking
Study: 8738661
Drug: 1% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% amino acid dialysis solution (AA-P)
Study: 8738661
Drug: 1.36% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.36% glucose dialysis solution (Glu-P)
Study: 7035052
Drug: Antihistamine-adrenergic combination
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-adrenergic combination
Study: 31893580
Drug: APO(a)‐LRx 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO(a)‐LRx 20 mg every 4 weeks
Study: 31893580
Drug: APO(a)‐LRx 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO(a)‐LRx 40 mg every 4 weeks
Study: 31893580
Drug: APO(a)‐LRx 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO(a)‐LRx 20 mg every 2 weeks
Study: 31893580
Drug: APO(a)‐LRx 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO(a)‐LRx 60 mg every 4 weeks
Study: 31893580
Drug: APO(a)‐LRx 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO(a)‐LRx 20 mg every week
Study: 26842692
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen plus IV narcotics
Study: 15818652
Drug: Ultrasound-guided local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided local corticosteroid injections (G1 group)
Study: 15818652
Drug: Standard local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard local corticosteroid injections without ultrasound guidance (G2 group)
Study: 7697275
Drug: BA +
Normalized name: Ba
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA + CS (combined beta 2‐agonist/corticosteroid therapy)
Study: 7697275
Drug: BA +
Normalized name: Ba
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA + AC (combined beta 2‐agonist/anticholinergic therapy)
Study: 7697275
Drug: BA +
Normalized name: Ba
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA + PL (beta 2‐agonist/placebo therapy)
Study: 28374186
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (vD3) at various doses
Study: 26564934
Drug: Self-administered CISS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered CISS
Study: 26564934
Drug: Practitioner-administered CISS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practitioner-administered CISS
Study: 19188545
Drug: Gemcitabine-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine-based chemotherapy
Study: 21232139
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of beef as a complementary food for 12 months
Study: 21232139
Drug: Micronutrient fortified
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronutrient fortified equi‐caloric rice‐soy cereal supplement for 12 months
Study: 17709062
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (SH, n=10)
Study: 11238476
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioactive iodine (131I) therapy (4.44 MBq/g thyroid)
Study: 11238476
Drug: Suppressive levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive levothyroxine treatment aiming at TSH values between 0.01 and 0.1 mU/L
Study: 11238476
Drug: Suppressive levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive levothyroxine treatment
Study: 3384075
Drug: Bambuterol 30
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 30 mg once daily
Study: 3384075
Drug: Terbutaline 5
Normalized name: terbutaline 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 5 mg sustained-release twice daily
Study: 18319414
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily
Study: 12741340
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of Sildenafil citrate (crushed and dissolved under the tongue) 15 minutes before planned sexual relations
Study: 12741340
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Sildenafil citrate (50-100 mg) 30 minutes before planned sexual relations
Study: 8618764
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with one drop of diclofenac sodium 0.1% four times per day for 3 days before surgery plus one drop of diclofenac sodium 0.1% every 15 minutes for four doses, beginning 1 hour before surgery.
Study: 8618764
Drug: No pretreatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pretreatment, but one drop of diclofenac sodium 0.1% every 15 minutes for four doses beginning 1 hour before surgery.
Study: 6377118
Drug: Hexabrix 320
DrugBank: Ioxaglic acid (DB09313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hexabrix 320 mg I/ml
Study: 24555511
Drug: Mentalization Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization Based Therapy for Eating Disorders (MBT-ED)
Study: 26342674
Drug: Perioperative FOLFOX
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative FOLFOX chemotherapy
Study: 20190349
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (50 g glucose)
Study: 20190349
Drug: Griffin's Fruitli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griffin's Fruitli bar (50 g available carbohydrate)
Study: 20190349
Drug: Peak Fuel's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak Fuel's Summit bar (50 g available carbohydrate)
Study: 18059578
Drug: Pre-test carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-test carbohydrate ingestion (CHO, 2x300 mL, 7% solution)
Study: 15012171
Drug: Pioglitazone 7.5/15/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 7.5/15/30 mg/day or 15/30/45 mg/day
Study: 15012171
Drug: Pioglitazone added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone added to metformin
Study: 15012171
Drug: Pioglitazone added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone added to insulin
Study: 15012171
Drug: Pioglitazone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone combined with metformin
Study: 15012171
Drug: Pioglitazone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone combined with insulin
Study: 11666121
Drug: TTFCA 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 60 mg thrice daily for 2 days before the flight, the day of the flight, and for another day after the flight
Study: 11666121
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug or other treatment)
Study: 9733274
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with intravenous diamorphine
Study: 9733274
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) with intravenous diamorphine
Study: 31568288
Drug: Large-gel-particle hyaluronic
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-gel-particle hyaluronic acid with 0.3% lidocaine, 20 mg/ml
Study: 26818364
Drug: 30% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% sucrose solution
Study: 20712499
Drug: Internet-based self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based self-administered program
Study: 12476093
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy (6 mg/m² body surface area)
Study: 12476093
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy (6 to 20 mg/m²)
Study: 10423707
Drug: 20-30 mmol/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-30 mmol/day of oral magnesium hydroxide
Study: 2655687
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both agents
Study: 2252453
Drug: Physostigmine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine treatment
Study: 6773843
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (1.2 g/day)
Study: 31065881
Drug: Daily partner‐focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily partner‐focused petitionary prayer (PFPP)
Study: 25714044
Drug: Gardasil (qHPV)
DrugBank: Human papillomavirus type 18 L1 capsid protein antigen (DB10302)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil (qHPV) booster dose
Study: 25714044
Drug: Cervarix (bHPV)
Normalized name: human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine Prefilled Syringe [Cervarix]
DrugBank: Human papillomavirus type 18 L1 capsid protein residues 2-472 antigen (DB10995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix (bHPV) booster dose
Study: 25406682
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with house-dust mite or grass pollen; applied for 2 years after a dose-up phase.
Study: 25406682
Drug: Placebo; applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; applied for 2 years after a dose-up phase.
Study: 22337568
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg preoperatively
Study: 14734464
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment (median duration of 13 months)
Study: 11964590
Drug: Morphine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.05 mg/kg bolus + 0.2 mg/kg infusion over 40 min)
Study: 11964590
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg bolus + 4 mg/kg infusion)
Study: 11964590
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (Diphenhydramine 10 mg bolus + 40 mg infusion)